Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vivani Medical, Inc. - Common Stock (NQ:VANI)

1.030 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 110
Open 1.030
Bid (Size) 1.030 (4)
Ask (Size) 1.050 (1)
Prev. Close 1.030
Today's Range 1.030 - 1.030
52wk Range 0.9054 - 2.090
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EXCLUSIVE: Vivani Medical Collaborates With Okava To Expand Development Of GLP-1 Therapy For Dogs
Vivani Medical and Okava expand GLP-1 therapy research to dogs, aiming to advance long-acting treatments for cardiometabolic conditions. 
Via Benzinga
Vivani Medical Announces Promising Preclinical Weight Loss Data For Its Semaglutide Implant: Retail Sentiment Soars
The company said on Wednesday that a single administration of the implant in healthy rats resulted in 20% lower body weight through a 91-day treatment period as compared to a control group that... 
Via Stocktwits

Performance

YTD
-14.2%
-14.2%
1 Month
-1.9%
-1.9%
3 Month
-12.7%
-12.7%
6 Month
-20.8%
-20.8%
1 Year
-36.8%
-36.8%

More News

Read More
EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing
Via Benzinga
Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
Via Benzinga
Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical To Spin Off Cortigent Neurostimulation Business To Create Better Focus On Individual Entities And Shareholder Value
Via Benzinga
Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia
Via Benzinga
Vivani Medical to Present at the Innovation in Obesity Therapeutics Summit West Coast
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
Via Benzinga
Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024
From Vivani Medical, Inc.
Via Business Wire
Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 Implant
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
Via Benzinga
Vivani Medical to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Vivani Medical, Inc.
Via Business Wire
VANI Stock Earnings: Vivani Medical Beats EPS for Q2 2024
Via InvestorPlace
Vivani Medical Provides Business Update and Reports Second Quarter 2024 Financial Results
From Vivani Medical, Inc.
Via Business Wire
Pineapple Financial And 1 Other Stock Under $1 Insiders Are Buying
Via Benzinga
Vivani Medical And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
From Vivani Medical, Inc.
Via Business Wire
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Via Benzinga

Frequently Asked Questions

Is Vivani Medical, Inc. - Common Stock publicly traded?
Yes, Vivani Medical, Inc. - Common Stock is publicly traded.
What exchange does Vivani Medical, Inc. - Common Stock trade on?
Vivani Medical, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vivani Medical, Inc. - Common Stock?
The ticker symbol for Vivani Medical, Inc. - Common Stock is VANI on the Nasdaq Stock Market
What is the current price of Vivani Medical, Inc. - Common Stock?
The current price of Vivani Medical, Inc. - Common Stock is 1.030
When was Vivani Medical, Inc. - Common Stock last traded?
The last trade of Vivani Medical, Inc. - Common Stock was at 04/29/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.